AI-generated · cited to primary sources · not investment advice · How we research
Unihealth Hosp
Our verdict on Unihealth Hosp isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The Navi Mumbai facility launch was delayed from the original July 2025 target to October 2025 due to statutory approval delays during the festive season. (2 revised across 2 tracked commitments)
“Navi Mumbai, we had anticipated it to be operational by July. We became operational in the first week of October. Actually, in Dussehra we did a soft launch and we became operational. The delay was due to certain statutory approvals, which took time.”
The Navi Mumbai hospital had a soft launch in October 2025 (a one-quarter delay from the June/July 2025 target) and became fully operational for critical services in mid-February 2026 after receiving ICU licenses. (1 revised across 1 tracked commitment)
“And we expect to operationally breakeven in Navi Mumbai sometime by the end of quarter 2 of this particular financial year. That's by 30th of September.”
While revenue grew, EBITDA margins saw a significant contraction in H2 FY25 compared to H2 FY24, dropping by 525 basis points. (1 missed across 1 tracked commitment)
“EBIDTA Margin (%) 35.92 41.16 -525 BPS”
The company is in active discussions for medical value travel partnerships with Air Tanzania and Myanmar Airlines.
“Partnership in Medical Value Travel Business Active discussions for a potential partnership in the Medical Value Travel business with Air Tanzania and Myanmar Airlines, aiming to enhance medical tourism.”
Targeting ARPOB of INR 32,000 to INR 35,000 for the Navi Mumbai facility. — target: INR 32,000 to INR 35,000 (+2 more commitments)
“The average revenue per occupied bed that will be the target for it would be in the range of about INR32,000 to INR35,000. This is a revised target from the earlier INR27,500 to INR30,000”
See the full cited Management analysis of Unihealth Hosp
How durable is the business?
The core hospital segment remains the dominant revenue driver, growing 14% year-over-year and maintaining a high revenue share of 82.19%. (2 expanding, 1 shifted)
“In FY25, Unihealth Hospitals Limited sustained its growth trajectory... Total Income (Hospital segment) FY24 (₹ Cr) 48.75, FY25 (₹ Cr) 55.59, YoY Growth 14.0%”
India operations are expanding with the commissioning of Navi Mumbai and the upcoming Nashik facility, aiming to reduce geographic concentration risk. (1 expanding, 1 stable)
“As we go forward into this financial year, the contribution from India is likely to increase significantly with Navi Mumbai, Nashik being functional.”
While total income grew, consolidated EBITDA margins saw a slight contraction from 38.29% in FY24 to 36.49% in FY25, likely due to pre-operative expenses for new facilities and higher raw material costs. (1 contracting, 3 expanding)
“EBITDA Margin FY24 38.29 FY25 36.49”
India revenue grew in absolute terms (₹7.87 Cr to ₹9.23 Cr) but its share of the total revenue mix remained relatively stable at approximately 15.8%. The upcoming Navi Mumbai hospital launch in June 2025 is the key catalyst for future share expansion. (1 stable, 1 expanding, 1 contracting)
“India FY25 9.23 FY24 7.87”
Uganda's revenue share has increased significantly, solidifying its position as the primary market. Revenue grew from ₹30.24 Cr to ₹43.49 Cr, now representing 74.45% of total revenue. (3 expanding, 1 contracting, 1 exited across 1 engine)
“For the full year FY26, consolidated total income increased by 34.6% to INR137 crores. EBITDA grew by nearly 49% to INR58.8 crores... Our diversified model spanning hospital operations, health care consultancy, pharmaceutical exports, medical value travel and health care infrastructure development continue to demonstrate its scalability and resilience.”
See the full cited Business Model analysis of Unihealth Hosp
Where does growth come from?
Medical tourism initiatives are accelerating through strategic partnerships like the Myanmar Airways International program to drive international patient flow to India. (3 accelerating, 2 new trend across 5 signals)
“there are more than 250 live inquiries that we are sitting on from a bunch of countries in Africa, whether it's Nigeria, Uganda, Tanzania, Kenya, so yes, the movement is there.”
The company is introducing high-end medical services like IVF and robotic surgeries, which typically command higher prices and improve profit margins.
“We recently did our first robotic total knee replacement also... highlighting the growing capabilities of our specialty health care programs.”
EBITDA margins have shown significant acceleration, increasing by 294 basis points year-on-year to 37.25% due to operational efficiencies and fixed-cost leverage. (4 accelerating, 1 decelerating across 5 signals)
“On a consolidated basis, as a mixture of mature facilities and recently commissioned facilities, we do expect the EBITDA margins to be in the early 30s even at that stage.”
A significant growth constraint is the long delay in receiving government payments in Uganda, which currently takes about 180 to 200 days to collect. — Receivable Days (Uganda): Targeting 150 days
“they're able to bring down the receivable days from 320 or to about somewhere around [200, 180... eventually, the target being 150 days.”
The company is re-entering the Medical Value Travel (MVT) space to internalize referrals from its African hospitals to its upcoming Indian facilities, aiming for 40%+ margins. (2 new trend across 2 signals)
“We have re-entered the space earlier last year... with UMC Hospitals being one of the front runners for getting that patient base into India... that margin will nearly double up. So, then we will be looking at a 40% plus margin.”
See the full cited Future Growth analysis of Unihealth Hosp
What could break the thesis?
Navi Mumbai is ramping up faster than expected, achieving ARPOB of INR 32,500 (vs INR 27,500 target) and is expected to breakeven by Q2 FY27. (1 easing)
“The occupancy at Navi Mumbai has been growing. And we expect to operationally breakeven in Navi Mumbai sometime by the end of quarter 2 of this particular financial year.”
Uganda revenue dipped 17% and PBT dropped 46% in H2 due to a 1.5-month productivity loss from the Christmas break and 5-year elections held in January. (1 stable)
“we did lose about 1.5 months of good productive period because of which there has been a consolidated dip in the overall revenue for H2. Now the decrease in PAT is more substantial... because the fixed costs remain the same.”
The risk is easing as net profit margins actually improved to 26% in FY25 (up from 20.47% in FY24). Management also aims to become debt-free in existing businesses by the end of FY26, which will mitigate interest cost pressures. (2 easing)
“EBITDA margins remained robust at 36%, and net profit margins improved to 26%, underscoring our focus on operational efficiency, cost discipline, and sustainable growth.”
The risk is easing. Despite expansion, Net Profit Margin improved significantly to 21.72% in H1 FY26 from 11.43% in H1 FY25. Finance costs actually decreased from ₹1.91 Cr to ₹1.18 Cr year-on-year. (1 easing, 1 stable)
“Net Profit Margin (%) H1 FY25 11.43, H1 FY26 21.72; Finance Costs H1 FY25 1.91, H1 FY26 1.18”
Uganda still contributes 80-85% of revenue, but the company is actively commissioning 250+ beds in India (Navi Mumbai and Nashik) and acquiring 100+ beds in Tanzania to bring Uganda's contribution below 33% within 5 years. (1 easing)
“right now, though, Uganda is contributing almost 80%, 85%. As we go forward into this financial year, the contribution from India is likely to increase significantly with Navi Mumbai, Nashik being functional.”
See the full cited Risk analysis of Unihealth Hosp
Unihealth Hosp analysis by filing period
Read the full thesis on Unihealth Hosp
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.